Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148480 | 0.82 | MAPT (0.40) | MAPTTP53FAAH | |
| SCHEMBL27968726 | 0.79 | TSHR (0.40) | TP53 | |
| SCHEMBL334795 | 0.77 | MAPT (0.44) | MAPTTP53FAAH | |
| SCHEMBL223705 | 0.77 | MAPT (0.44) | MAPTTP53FAAH | |
| SCHEMBL15087065 | 0.77 | MAPT (0.47) | MAPTFAAH | |
| SCHEMBL15087067 | 0.77 | MAPT (0.47) | MAPTFAAH | |
| SCHEMBL1930754 | 0.77 | MAPT (0.47) | MAPTFAAH | |
| SCHEMBL7074879 | 0.77 | TSHR (0.42) | MAPTFAAH | |
| SCHEMBL702238 | 0.76 | MAPT (0.42) | MAPTTP53FAAH | |
| SCHEMBL3453813 | 0.76 | MAPT (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9801888-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2017-10-31 | — | — | US | disclosed |
| EP-2519102-B1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEV CENTER BIOTECHNOLOGY (TW) | 2016-10-19 | — | — | EP | disclosed |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-05-19 | — | — | US | disclosed |
| US-9315491-B2 | Pyrimidine compounds as mTOR and PI3K inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2016-04-19 | — | — | US | disclosed |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
| EP-2519102-A2 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | Development Center For Biotechnology (TW) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080568-A2 | NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-07-07 | — | — | WO | disclosed |
| WO-2006011647-A1 | POLYMERIZABLE COMPOSITION, OPTICALLY ANISOTROPIC LAYER AND METHOD FOR MANUFACTURING THEREOF, OPTICAL COMPENSATORY ELEMENT, LIQUID CRYSTAL DISPLAY AND LIQUID CRYSTAL PROJECTOR | FUJIFILM CORPORATION (JP) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MAPT 3532/4885TP53 1198/4885FAAH 4327/4885 |
| US-20160136176-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MAPT 3532/4885TP53 1198/4885FAAH 4327/4885 |
| US-20140178360-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MAPT 3532/4885TP53 1198/4885FAAH 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.